Abstract
Transforming growth factor-β (TGF-β) is an important physiologic regulator of cell growth and differentiation. TGF-β has been shown to inhibit the proliferation of quiescent hematopoietic stem cells and stimulate the differentiation of late progenitors to erythroid and myeloid cells. Insensitivity to TGF-β is implicated in the pathogenesis of many myeloid and lymphoid neoplasms. Loss of extracellular TGF receptors and disruption of intracellular TGF-β signaling by oncogenes is seen in a variety of malignant and premalignant states. TGF-β can also affect tumor growth and survival by influencing the secretion of other growth factors and manipulation of the tumor microenvironment. Recent development of small molecule inhibitors of TGF-β receptors and other signaling intermediaries may allow us to modulate TGF signaling for future therapeutic interventions in cancer.
Get full access to this article
View all access options for this article.